Tag Archives: Ixempra
FDA Approves Halaven for Late-Stage Breast Cancer
Good news for patients with late stage metastatic breast cancer. The US Food and Drug Administration (FDA) approved eribulin mesylate injection (Halaven; Eisai, Inc) for the treatment of metastatic breast cancer in patients who have received at least 2 prior … Continue reading →
Posted in Breast cancer, Cancer
|
Tagged anthracycline, Bristol-Myers Squibb, capecitabine, chemotherapy, Eisai, eribulin, Halaven, ixabepilone, Ixempra, Metastatic breast cancer, paclitaxel, resistant, Roche, Survival, taxane, Xeloda
|
Comments Off on FDA Approves Halaven for Late-Stage Breast Cancer